Floatz logo

DACTOLISIB

Metastatic Breast Cancer

Novartis PharmaceuticalsSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
73/ 100

Competitive context

891 Active assets in the Metastatic Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Loratadine
Noha Mansour
Phase 2BB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

DACTOLISIB is also rated in:

castration-resistant prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
pancreatic neuroendocrine tumorDormant
CCC
Indicative ·
51 / 100
View asset →
renal cell carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →